MIO Consult training

Courses & Workshops

Explore the course outlines and register your interest to be notified when the relevant registration route is ready. Public booking, payment, enrolment and cohort selection are not yet open. Corporate and in-house enquiries remain welcome.

01Public courses

Course outlines are available now. Register interest to hear when a tested registration route opens.

02Corporate / in-house

For three or more participants, with invoice billing and tailored delivery where the group needs examples adapted.

03Frameworks course

In development. Join the interest list to receive the approved outline and registration route when ready.

Revenue recognition

Mastering Revenue Recognition for Biotech Licensing Deals

For senior accounting, finance, partnering and business-development professionals working with biotech licensing structures where milestones, royalties, collaboration terms and performance obligations drive the accounting answer.

Registration not yet open Dates and prices will be published only after approval.
Who it is for

Finance, accounting, partnering and business-development teams dealing with out-licensing, collaboration and revenue-side judgement.

Why it matters

Milestone payments, royalties and territorial rights can create accounting conclusions that affect revenue, audit readiness and deal economics for years.

  • IFRS 15 analysis of licences, services and performance obligations.
  • Milestone payments, tiered royalties and variable consideration constraints.
  • Multi-territory and collaboration arrangements that create compliance risk.
  • Audit-ready revenue recognition rationale using practical licensing scenarios.
Course focus

How to move from contract terms to a defensible IFRS 15 conclusion for biotech licensing arrangements, including licence-versus-service analysis, performance obligations and variable consideration.

Participant outcome

Participants should leave with a clearer framework for identifying revenue-recognition risk before audit review, financing diligence or investor reporting pressure exposes it.

In-licensing / BDL

Financial Strategies for Pharma, Med-Tech & Biotech In-Licensing Deals

For business-development, legal and finance professionals who need to understand how in-licensing terms translate into financial-statement consequences before a deal is signed.

Registration not yet open Dates and prices will be published only after approval.
Who it is for

Business-development, legal, alliance and finance professionals involved in in-licensing negotiations and deal assessment.

Why it matters

The way rights, obligations and economics are drafted in an in-licensing deal can influence valuation, capitalisation, expense treatment and post-signing reporting.

  • Financial and accounting terminology used in in-licensing negotiations.
  • How rights, obligations, upfront payments, milestones and option mechanics affect valuation and reported performance.
  • In-licensing accounting signals around IP classification, asset acquisition, capitalisation and expense.
  • Questions to raise before in-licensing terms are locked and negotiation flexibility disappears.
Course focus

How business-development, legal and finance teams can read in-licensing terms for accounting consequences before the term sheet hardens.

Participant outcome

Participants should leave able to spot where acquired rights, obligations, milestones, exclusivity and payment design may affect valuation, capitalisation, expense treatment and negotiation flexibility.

Licensing deals

Licensing Deal Accounting in Practice: Pharma, Med-Tech & Biotech

A practical course for finance and accounting professionals who need to analyse licensing deal terms, choose the right accounting model, and document the judgement clearly. It builds on the former Unravelling Accounting Secrets material and adds a structured transaction-accounting framework.

Coming soon No active date, price or registration route is displayed.
Who it is for

Finance, accounting, group reporting, technical accounting and controllership teams working through signed or near-signed licensing arrangements.

Why it matters

One agreement can raise asset acquisition, collaboration, revenue, equity, cost-sharing, capitalisation and audit-evidence questions at the same time.

  • Deal-term mapping across upfront payments, milestones, royalties, options, cost sharing, equity features and asset exchanges.
  • In-licensing accounting: IP classification, capitalisation, expense treatment, amortisation and impairment triggers.
  • Out-licensing and revenue-side triage: customer versus collaborator, performance obligations, variable consideration and royalties.
  • Framework application block for turning the analysis into a file-ready position paper.
Course focus

A repeatable framework for moving from deal facts to accounting model, financial-statement effect and file-ready conclusion.

Participant outcome

Participants should leave with a practical issue map, position-paper structure and auditor challenge checklist for licensing deal accounting.

Frameworks

Transaction Accounting Frameworks Course

The frameworks course is in development. Join the interest list to be notified when the course outline, date and registration route are ready.

Corporate and in-house groups

For three or more participants, or where finance, alliance management and business-development teams need a shared read of their own deal book, request invoice billing or an in-house course. Dates are locked in advance, and examples/content can be adjusted where the engagement requires it.

Discuss an in-house course